Biotech Values

[DewDiligence]

MNTA’s lawsuit has a business rather than a regulatory impetus, IMO. I would be willing to bet MNTA knows that Teva’s Lovenox knockoff is not going to pass muster with the FDA. However, the uncertainty surrounding Teva’s assertions vis-à-vis Lovenox—and the parroting of these assertions by some sell-side analysts—has undermined the conduct of MNTA’s business and, in particular, has made it harder for MNTA to ink partnership deals for FoB’s, M118, and M402.

To get full value for its proprietary technology, MNTA must convince prospective partners that the technology is both valuable and unique, whch is hard to accomplish while Teva is publicly spouting BS about its own Lovenox application.